Baxter Healthcare Corporation: Clindamycin Injection Usp In 5% Dextrose, 900 Mg/50 Ml (18 Mg/ml), In Galaxy
Recall Summary Baxter Healthcare is recalling Clindamycin Injection USP (900 mg/50 mL) distributed nationwide across all U.S. states, Puerto Rico, and Chile due to manufacturing quality deviations. This is a Class II recall, meaning there is a potential health risk but the product is not expected to cause serious adverse effects. The recall affects this specific antibiotic injectable medication used in hospitals and healthcare settings.
- Recalling firm
- Baxter Healthcare Corporation
- Product
- Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Manufactured by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-4114-50.
- Reason
- CGMP Deviations
- Classification
- Class II
- Category
- drug recall
- Country
- United States
- Agency
- U.S. Food and Drug Administration
- Recall date
- 2026-08-06
- Status
- Ongoing
- Areas affected
- AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, ...
- Distribution
- US Nationwide; Puerto Rico; and Chile.
Official recall notice from U.S. Food and Drug Administration
Recall details on Nibble Recalls: https://trynibble.app/recalls/8af34d8f-ea55-48cc-9835-0dd8c7bd41f3